Islet Sciences Inc (NASDAQ:ONCE) Sentiment Change Report at 1.43

May 16, 2018 - By Robert Reynolds

Spark Therapeutics, Inc. (NASDAQ:ONCE) Corporate Logo

“Big money” Positions

“Big money sentiment for Islet Sciences Inc (NASDAQ:ONCE) in Q4 2017 decreased to 1.43, SEC filings reveal. That’s down -1.51, from 2017Q3’s 2.94. 96 hedge funds increased or started new equity positions, while 67 sold and reduced stakes in Islet Sciences Inc so the sentiment turned negative. Funds own 35.76 million shares, up from 33.64 million shares in 2017Q3. Funds holding Islet Sciences Inc in top 10 decreased from 1 to 0 for a decrease of 1. 41 Investors Sold All; 26 Reduced Holdings; 55 increased holdings while 41 hedge funds bought holdings.

Most Islet Sciences Inc Investors

Great Point Partners Llc owns 410,900 shares in Islet Sciences Inc as of Q4 2017. As of Q4 2017, 615,000 shares of Islet Sciences Inc are owned by Rock Springs Capital Management Lp. In addition, Eventide Asset Management Llc reported 324,000 shares in Islet Sciences Inc equivalent to 0.87% of its US equity exposure. The New York-based fund Baker Bros. Advisors Lp have invested about 0.62% of the active investment manager’s stock portfolio in Islet Sciences Inc. The Israel-based fund Sphera Funds Management Ltd. looks positive on Islet Sciences Inc, owning 100,000 shares.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.The company has $2.92 billion market cap. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.Currently it has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

ONCE is touching $78.015 during the last trading session, after increased 0.91%.Currently Spark Therapeutics, Inc. is uptrending after 21.52% change in last May 16, 2017. ONCE has 213,077 shares volume. ONCE outperformed the S&P500 by 9.97%.

Spark Therapeutics, Inc. (NASDAQ:ONCE)’s earnings release is expected by WallStreet on August, 1, as reported by RTT. Analysts expect change of 78.31 % or $1.48 from previous year’s $-1.89 earnings per share compared to current’s $-0.41 earnings per share. Last quarter $-1.25 earnings per share was reported. Analysts sees -67.20 % EPS growth this quarter.

Balyasny Asset holds 58,180 shs. Virtu Fincl Limited Liability Co, a New York-based fund reported 25,699 shs. Rmb Capital Management Ltd Liability Com has 0.03% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Blair William & Il has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Massachusetts-based Eventide Asset Mgmt Lc has invested 0.87% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Voya Invest Mngmt Limited Liability has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Group Incorporated One Trading L P holds 0.04% of its capital in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 116,321 shs. 3,575 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Wells Fargo Mn holds 0% of its capital in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 253,563 shs. Sabby Mgmt Ltd Company accumulated 110,827 shs. Moreover, Rock Springs Cap Ltd Partnership has 1.43% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 615,000 shs. Sei Invests stated it has 129 shs or 0% of all its holdings. Rhenman And Prtn Asset Mgmt Ab holds 0.49% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 70,200 shs. Metropolitan Life Ins Commerce New York has invested 0.01% of its capital in Spark Therapeutics, Inc. (NASDAQ:ONCE). Amer Group invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE).

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Total analysts of 18 have positions in Spark Therapeutics (NASDAQ:ONCE) as follows: 10 rated it a “Buy”, 1 with “Sell” and 7 with “Hold”. The positive are 56%. Since December 11, 2017 according to StockzIntelligence Inc Spark Therapeutics has 35 analyst reports. In Tuesday, February 20 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Wednesday, February 14 the firm earned “Neutral” rating by JP Morgan. On Thursday, January 25 the rating was maintained by Barclays Capital with “Overweight”. In Monday, April 30 report Cantor Fitzgerald maintained it with “Buy” rating and $10300 target. On Wednesday, February 21 the rating was maintained by Bernstein with “Buy”. The stock rating was maintained by Cowen & Co with “Buy” on Wednesday, January 3. On Monday, December 11 the stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given by Cantor Fitzgerald. On Monday, December 11 the company was maintained by J.P. Morgan. On Monday, December 11 RBC Capital Markets maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating. RBC Capital Markets has “Buy” rating and $68.0 target. On Wednesday, February 21 Stifel Nicolaus maintained the shares of ONCE in report with “Buy” rating.

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were released by, and The first one has “Spark Therapeutics 2018 Q1 – Results – Earnings Call Slides” as a title and was released on May 08, 2018. The next is “Spark Therapeutics’ (ONCE) CEO Jeff Marrazzo on Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. And last was released on May 14, 2018, called “Genomic Medicine: Catch The Gene Therapy Wave”.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.